Actionable news
0
All posts from Actionable news
Actionable news in GILD: Gilead Sciences, Inc.,

Why Investors Are Underestimating Gilead Sciences

The majority of attention focused by investors on Gilead Sciences (NASDAQ:GILD) is related to its top-selling hepatitis C drugs. While those treatments generate more than $19 billion in annual revenue for the company, their sales have slowed amid growing competition. However, avoiding Gilead Sciences based on that may cost you a chance to profit.

In this clip from The Motley Fool's Industry Focus: Healthcare podcast, analyst Kristine Harjes and contributor Todd Campbell discuss why investors might want to look beyond the company's short-term sales slowdown and add shares for the long haul.

A transcript follows the video.

This podcast was recorded on Jul. 1, 2016.

Kristine Harjes: You mentioned that we've seen a little bit of a slowdown in hepatitis C, and because of that, this stock is so cheap. I mean, really, the market, I think, is tremendously under-appreciating Gilead Sciences. The headline story right now is: "Oh, no, Harvoni sales have fallen 50% year-over-year in the U.S." I just am not that concerned about it. I mean, you've got Epclusa coming in now, but even more importantly, there is so much more to...


More